Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Melanoma Affects the Composition of Blood Cell-Derived Extracellular Vesicles.

Koliha N, Heider U, Ozimkowski T, Wiemann M, Bosio A, Wild S.

Front Immunol. 2016 Jul 26;7:282. doi: 10.3389/fimmu.2016.00282. eCollection 2016.

2.

A novel multiplex bead-based platform highlights the diversity of extracellular vesicles.

Koliha N, Wiencek Y, Heider U, Jüngst C, Kladt N, Krauthäuser S, Johnston IC, Bosio A, Schauss A, Wild S.

J Extracell Vesicles. 2016 Feb 19;5:29975. doi: 10.3402/jev.v5.29975. eCollection 2016.

3.

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling.

Kaiser MF, Heider U, Mieth M, Zang C, von Metzler I, Sezer O.

Eur J Haematol. 2013 Apr;90(4):263-72. doi: 10.1111/ejh.12069. Epub 2013 Feb 15.

PMID:
23311753
4.

The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.

Lamottke B, Kaiser M, Mieth M, Heider U, Gao Z, Nikolova Z, Jensen MR, Sterz J, von Metzler I, Sezer O.

Eur J Haematol. 2012 May;88(5):406-15. doi: 10.1111/j.1600-0609.2012.01764.x. Epub 2012 Mar 21.

PMID:
22309072
5.

BSc2118 is a novel proteasome inhibitor with activity against multiple myeloma.

Sterz J, Jakob C, Kuckelkorn U, Heider U, Mieth M, Kleeberg L, Kaiser M, Kloetzel PM, Sezer O, von Metzler I.

Eur J Haematol. 2010 Aug;85(2):99-107. doi: 10.1111/j.1600-0609.2010.01450.x. Epub 2010 Mar 31.

PMID:
20374272
6.

Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib.

Heider U, Rademacher J, Kaiser M, Kleeberg L, von Metzler I, Sezer O.

Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):134-7. doi: 10.3816/CLML.2010.n.019.

PMID:
20371447
7.

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma.

Kaiser M, Lamottke B, Mieth M, Jensen MR, Quadt C, Garcia-Echeverria C, Atadja P, Heider U, von Metzler I, Türkmen S, Sezer O.

Eur J Haematol. 2010 Apr;84(4):337-44. doi: 10.1111/j.1600-0609.2009.01403.x. Epub 2009 Dec 17.

PMID:
20028416
8.

Serum levels of total-RANKL in multiple myeloma.

Jakob C, Goerke A, Terpos E, Sterz J, Heider U, Kühnhardt D, Ziefle S, Kleeberg L, Mieth M, Metzler Iv, Müller C, Sezer O.

Clin Lymphoma Myeloma. 2009 Dec;9(6):430-5. doi: 10.3816/CLM.2009.n.085.

PMID:
19951882
9.

Therapeutic implication of BAL in patients with neutropenia.

Kuehnhardt D, Hannemann M, Schmidt B, Heider U, Possinger K, Eucker J.

Ann Hematol. 2009 Dec;88(12):1249-56. doi: 10.1007/s00277-009-0747-1. Epub 2009 May 5.

PMID:
19415277
10.

Synergistic interaction of proteasome and topoisomerase II inhibition in multiple myeloma.

von Metzler I, Heider U, Mieth M, Lamottke B, Kaiser M, Jakob C, Sezer O.

Exp Cell Res. 2009 Aug 15;315(14):2471-8. doi: 10.1016/j.yexcr.2009.04.019. Epub 2009 May 3.

PMID:
19410573
11.

Novel renal replacement strategies for the elimination of serum free light chains in patients with kappa light chain nephropathy.

Kleeberg L, Morgera S, Jakob C, Hocher B, Schneider M, Peters H, Rötzer S, Müller C, Kaiser M, Fleissner C, Heider U, Neumayer HH, Sezer O.

Eur J Med Res. 2009;14:47-54.

12.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in cutaneous T cell lymphoma.

Heider U, Rademacher J, Lamottke B, Mieth M, Moebs M, von Metzler I, Assaf C, Sezer O.

Eur J Haematol. 2009 Jun;82(6):440-9. doi: 10.1111/j.1600-0609.2009.01239.x. Epub 2009 Feb 10.

PMID:
19220424
13.

Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.

Heider U, Kaiser M, Mieth M, Lamottke B, Rademacher J, Jakob C, Braendle E, Stover D, Sezer O.

Eur J Haematol. 2009 Jan;82(1):31-8. doi: 10.1111/j.1600-0609.2008.01164.x. Epub 2008 Nov 10.

PMID:
19067746
14.

Curcumin diminishes human osteoclastogenesis by inhibition of the signalosome-associated I kappaB kinase.

von Metzler I, Krebbel H, Kuckelkorn U, Heider U, Jakob C, Kaiser M, Fleissner C, Terpos E, Sezer O.

J Cancer Res Clin Oncol. 2009 Feb;135(2):173-9. doi: 10.1007/s00432-008-0461-8. Epub 2008 Sep 3.

PMID:
18766375
15.

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma.

Jakob C, Sterz J, Liebisch P, Mieth M, Rademacher J, Goerke A, Heider U, Fleissner C, Kaiser M, von Metzler I, Müller C, Sezer O.

Leukemia. 2008 Sep;22(9):1767-72. doi: 10.1038/leu.2008.159. Epub 2008 Jun 26. Erratum in: Leukemia. 2008 Sep;22(9):1812.

PMID:
18580957
16.

Notch inhibition blocks multiple myeloma cell-induced osteoclast activation.

Schwarzer R, Kaiser M, Acikgoez O, Heider U, Mathas S, Preissner R, Sezer O, Doerken B, Jundt F.

Leukemia. 2008 Dec;22(12):2273-7. doi: 10.1038/leu.2008.138. Epub 2008 Jun 5. No abstract available.

PMID:
18528422
17.

The potential of proteasome inhibitors in cancer therapy.

Sterz J, von Metzler I, Hahne JC, Lamottke B, Rademacher J, Heider U, Terpos E, Sezer O.

Expert Opin Investig Drugs. 2008 Jun;17(6):879-95. doi: 10.1517/13543784.17.6.879 . Review.

PMID:
18491989
18.

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

Kaiser M, Mieth M, Liebisch P, Oberländer R, Rademacher J, Jakob C, Kleeberg L, Fleissner C, Braendle E, Peters M, Stover D, Sezer O, Heider U.

Eur J Haematol. 2008 Jun;80(6):490-4. doi: 10.1111/j.1600-0609.2008.01065.x. Epub 2008 Mar 10.

PMID:
18331598
19.

The mitochondrial heat shock protein 60 (HSP60) is up-regulated in Onchocerca volvulus after the depletion of Wolbachia.

Pfarr KM, Heider U, Schmetz C, Büttner DW, Hoerauf A.

Parasitology. 2008 Apr;135(4):529-38. doi: 10.1017/S003118200700409X. Epub 2008 Jan 21.

PMID:
18205985
20.

Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.

Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.

Eur J Haematol. 2008 Feb;80(2):133-42. Epub 2007 Dec 20.

PMID:
18005386
21.

Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects.

Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Brockmöller J, Kaiser R.

Clin Pharmacol Ther. 2008 May;83(5):749-57. Epub 2007 Oct 3. Erratum in: Clin Pharmacol Ther. 2009 Sep;86(3):340.

PMID:
17914442
22.

Molecular and clinical aspects of proteasome inhibition in the treatment of cancer.

Zavrski I, Jakob C, Kaiser M, Fleissner C, Heider U, Sezer O.

Recent Results Cancer Res. 2007;176:165-76. Review.

PMID:
17607924
23.
24.

Bortezomib inhibits human osteoclastogenesis.

von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M, Kaiser M, Jakob C, Sterz J, Kleeberg L, Heider U, Sezer O.

Leukemia. 2007 Sep;21(9):2025-34. Epub 2007 Jun 21.

PMID:
17581612
25.

Genetic polymorphisms in the amino acid transporters LAT1 and LAT2 in relation to the pharmacokinetics and side effects of melphalan.

Kühne A, Kaiser R, Schirmer M, Heider U, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Sezer O, Brockmöller J.

Pharmacogenet Genomics. 2007 Jul;17(7):505-17.

PMID:
17558306
26.

Proteasome as an emerging therapeutic target in cancer.

Zavrski I, Kleeberg L, Kaiser M, Fleissner C, Heider U, Sterz J, Jakob C, Sezer O.

Curr Pharm Des. 2007;13(5):471-85. Review.

PMID:
17348844
27.

Circulating proteasome levels are an independent prognostic factor for survival in multiple myeloma.

Jakob C, Egerer K, Liebisch P, Türkmen S, Zavrski I, Kuckelkorn U, Heider U, Kaiser M, Fleissner C, Sterz J, Kleeberg L, Feist E, Burmester GR, Kloetzel PM, Sezer O.

Blood. 2007 Mar 1;109(5):2100-5. Epub 2006 Nov 9.

28.

Peroxisome proliferator-activated receptor-gamma ligands inhibit proliferation and induce apoptosis in mantle cell lymphoma.

Eucker J, Sterz J, Krebbel H, Zavrski I, Kaiser M, Zang C, Heider U, Jakob C, Elstner E, Sezer O.

Anticancer Drugs. 2006 Aug;17(7):763-9.

PMID:
16926626
29.

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment.

Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz CO, Fleissner C, Hecht M, Sezer O.

Eur J Haematol. 2006 Sep;77(3):233-8.

PMID:
16923110
30.

Angiogenesis in multiple myeloma.

Jakob C, Sterz J, Zavrski I, Heider U, Kleeberg L, Fleissner C, Kaiser M, Sezer O.

Eur J Cancer. 2006 Jul;42(11):1581-90. Epub 2006 Jun 23. Review.

PMID:
16797965
31.

Bone markers in multiple myeloma.

Heider U, Fleissner C, Zavrski I, Kaiser M, Hecht M, Jakob C, Sezer O.

Eur J Cancer. 2006 Jul;42(11):1544-53. Epub 2006 Jun 9. Review.

PMID:
16765040
32.
33.

RNAi mediated silencing of actin expression in adult Litomosoides sigmodontis is specific, persistent and results in a phenotype.

Pfarr K, Heider U, Hoerauf A.

Int J Parasitol. 2006 May 31;36(6):661-9. Epub 2006 Mar 6.

PMID:
16546192
34.

The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma.

Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, Sezer O, Heider U.

Haematologica. 2006 Feb;91(2):248-51.

35.

Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma.

Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O.

Eur J Haematol. 2006 Jan;76(1):42-50.

PMID:
16343270
36.

Structure of a halophilic nucleoside diphosphate kinase from Halobacterium salinarum.

Besir H, Zeth K, Bracher A, Heider U, Ishibashi M, Tokunaga M, Oesterhelt D.

FEBS Lett. 2005 Dec 5;579(29):6595-600. Epub 2005 Nov 9.

37.

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease.

Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O.

Biochem Biophys Res Commun. 2005 Dec 16;338(2):687-93. Epub 2005 Oct 3. Review.

PMID:
16216218
38.

Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome P450 2C19.

Timm R, Kaiser R, Lötsch J, Heider U, Sezer O, Weisz K, Montemurro M, Roots I, Cascorbi I.

Pharmacogenomics J. 2005;5(6):365-73.

PMID:
16116487
39.

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function.

Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, Sezer O.

Biochem Biophys Res Commun. 2005 Jul 22;333(1):200-5.

PMID:
15936724
40.

Ligands of peroxisome proliferator-activated receptor gamma induce apoptosis in multiple myeloma.

Eucker J, Bängeroth K, Zavrski I, Krebbel H, Zang C, Heider U, Jakob C, Elstner E, Possinger K, Sezer O.

Anticancer Drugs. 2004 Nov;15(10):955-60.

PMID:
15514564
41.

Expression, crystallization and crystallographic analysis of DegS, a stress sensor of the bacterial periplasm.

Grininger M, Ravelli RB, Heider U, Zeth K.

Acta Crystallogr D Biol Crystallogr. 2004 Aug;60(Pt 8):1429-31. Epub 2004 Jul 21.

PMID:
15272167
42.

Expression of receptor activator of NF-kappaB ligand (RANKL) mRNA in human multiple myeloma cells.

Heider U, Zavrski I, Jakob C, Bängeroth K, Fleissner C, Langelotz C, Possinger K, Hofbauer LC, Viereck V, Sezer O.

J Cancer Res Clin Oncol. 2004 Aug;130(8):469-74. Epub 2004 Jun 15.

PMID:
15205949
43.

Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.

Heider U, Fleissner C, Zavrski I, Jakob C, Dietzel T, Eucker J, Ockenga J, Possinger K, Sezer O.

Eur J Haematol. 2004 Jan;72(1):64-6.

PMID:
14962266
44.

Identification and clinical relevance of receptor activator of nuclear factor kappaB ligand expression of myeloma cells.

Heider U, Zavrski I, Jakob C, Fleissner C, Sezer O.

Cancer Res. 2004 Jan 15;64(2):773-4; author reply 774-5. No abstract available.

45.

Liposomal daunorubicin (DaunoXome) in multiple myeloma: a modified VAD regimen using short-term infusion.

Eucker J, Eikel D, Heider U, Jakob C, Zavrski I, Gatz F, Mergenthaler HG, Jungclas H, Possinger K, Sezer O.

Anticancer Drugs. 2003 Nov;14(10):793-9.

PMID:
14597873
46.

Bisphosphonates in early multiple myeloma.

Sezer O, Jakob C, Zavrski I, Heider U, Fleissner C, Freund M.

Eur J Haematol. 2003 Sep;71(3):231-2. No abstract available.

PMID:
12930327
47.
48.

Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion.

Zavrski I, Naujokat C, Niemöller K, Jakob C, Heider U, Langelotz C, Fleissner C, Eucker J, Possinger K, Sezer O.

J Cancer Res Clin Oncol. 2003 Jul;129(7):383-91. Epub 2003 Jul 8.

PMID:
12851815
49.

Expression of high-mobility-group-protein HMGI-C mRNA in the peripheral blood is an independent poor prognostic indicator for survival in metastatic breast cancer.

Langelotz C, Schmid P, Jakob C, Heider U, Wernecke KD, Possinger K, Sezer O.

Br J Cancer. 2003 May 6;88(9):1406-10.

50.

Circulating hepatocyte growth factor levels in multiple myeloma.

Jakob C, Fleissner C, Zavrski I, Heider U, Possinger K, Sezer O.

Br J Haematol. 2003 May;121(3):532. No abstract available.

PMID:
12716383

Supplemental Content

Loading ...
Support Center